Zai Lab (09688) saw its shares climb 7.16% in the morning session, currently trading at HK$15.71, with a turnover of HK$197 million.

According to an announcement on Zai Lab's official WeChat account, on January 13, the company presented its 2026 strategic priorities and clinical development progress at the 44th Annual JPMorgan Healthcare Conference, with related content scheduled for a presentation on January 14 at 7:00 AM Beijing Time. Notably, Zocilurtatug pelitecan (Zoci) has the potential to become Zai Lab's first globally launched product in oncology, with plans to initiate three registrational pivotal studies by the end of 2026, targeting second-line and later small cell lung cancer, first-line small cell lung cancer, and neuroendocrine carcinoma.

Currently, Zai Lab boasts a portfolio of eight commercialized products in China, forming a diversified and sustainable commercial pipeline. The company anticipates the launch of Enobosarm Trichloride Capsules in the first half of 2026 through a focused and efficient commercialization strategy, emphasizing physician education, real-world evidence generation, and preparation for potential inclusion in the National Reimbursement Drug List in 2027. Other products expected to launch in the near term, such as povetacicept and elegrobart (VRDN-003), are set to further drive regional business growth.